Effects of Telmisartan compared with Candesartan on ischemic cardiovascular events in high-risk hypertensive patients: a multi-center, prospective, randomized, open-labeled, blinded endpoints trial
- Conditions
- Essential hypertension
- Registration Number
- JPRN-UMIN000001762
- Lead Sponsor
- Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1500
Not provided
The exclusion criteria are set as follow: 1.History of worsening of heart failure within the preceding 6 months 2.Planned elective percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the anteceding 3 months 3.History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the preceding 12 months 4.History of percutaneous hind limb angioplasty (PTA) or bypass grafting within the preceding 6 months 5.History of cerebral infarction, cerebral hemorrhage within the past 6 months 6.Congenital heart disease 7.Uncontrolled hypertension on treatment (eg, BP>180/110 mmHg) 8.Pregnant women or women of childbearing potential 9.Hepatic dysfunction (AST or ALT >100IU/L) 10.Renal impairment (serum creatinine level >2.0 mg per 100 ml) 11.Known hypersensitivity or intolerance to ARB
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ew or recurrent acute myocardial infarction, angina pectoris, and asymptomatic myocardial ischemia
- Secondary Outcome Measures
Name Time Method All causes of mortality, cardiovascular death (myocardial infarction, stroke, aortic dissection, aortic rupture, etc.) New or recurrent stroke or peripheral artery diseases, new occurrence of diabetes mellitus